Observed Signal · Oct 28, 2026 · Earnings Report · Source: CNBC Investing · Impact: 1/5 · Sentiment: Neutral
Biotech IPOs Surge in 2026, But Risks Remain High
Despite a sluggish IPO market, biotech companies have bucked the trend in 2026, with 26 U.S. IPOs, more than double the 2025 tally and the highest since 2021. However, historical performance of the 2020 biotech IPO class shows only 16% positive returns and 44% plunging 90% or more. Factors driving the activity include M&A by large pharma and hot markets like GLP-1 drugs, plus biotech's insulation from market headwinds. The article highlights success stories like Revolution Medicines, but also failures like LeonaBio and Codiak Biosciences. Investors are advised to focus on 'picks and shovels' companies like Veeva Systems and to consider clinical stage, pipeline, and management experience. The sector's momentum may persist with at least four more offerings in the pipeline.
News about biotech IPOs is not directly relevant to AdTech, MarTech, or digital advertising. The article focuses on financial markets and biotech industry, with no implications for the ad tech ecosystem.
Track Anthropic Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- 26 biotech companies went public in the U.S. in 2026, more than double 2025's tally and the highest annual count since 2021.
- CNBC review of the 2020 biotech IPO class found only 16% delivered positive returns, while 44% plunged 90% or more.
- Revolution Medicines, a 2020 IPO, has delivered about 1,000% return as of Friday, backed by FDA approval for Rasonque.
- LeonaBio (formerly Athira Pharmaceuticals) is down 97% since its 2020 IPO after product failures and CEO resignation.
- The iShares Biotechnology ETF (IBB) is up 35% in 2026 after a 28% gain in 2025.
- Veeva Systems, a cloud software provider for life sciences, is highlighted as a potential 'picks and shovels' play.
Connected Companies & Entities
“Excitement around the highly anticipated Anthropic IPO”
“OpenAI ruled out a 2026 IPO”
“SB Energy delayed their debut”
“IPO prospect Nscale pressured by investors to cut its valuation”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Global IPO proceeds hit record high in 2026
According to EY's latest IPO Barometer, global IPO proceeds reached a record high in the first nine months of 2026, totaling $287.5 billion, a 151% increase year-over-year, despite a slight decline in the number of IPOs (888 vs. 922). The third quarter alone saw $93.3 billion raised across 367 deals, with large listings such as SK Hynix's $26.5 billion IPO on Nasdaq driving growth. China and Europe saw significant increases in both deal count and volume, while the US saw fewer IPOs but a 395% surge in proceeds to $163 billion. Germany recorded eight IPOs, including SMAG Mobile Antenna Masts and Helios Solar. Technology and advanced manufacturing dominated, with investors favoring sectors like AI, robotics, and energy. The outlook for Q4 remains cautiously positive.
IPO Winter at Wall Street: All Eyes on Anthropic
The IPO market is experiencing a severe slowdown despite record overall volumes, with many companies postponing or canceling their listings. The primary cause is investor focus on Anthropic's upcoming IPO, expected in mid-November, which is overshadowing other candidates. Notable postponements include EG Group, Oura, SB Energy, Holtec, and Bamboo Insurance. OpenAI has pushed its IPO to 2027. While mega-deals like SpaceX's $86B IPO and SK Hynix's $26.5B listing drove high proceeds, tech listings are trading 23% below first-day prices on average, indicating post-IPO performance concerns. The slowdown is global, affecting Europe and Asia, with companies like Waterstones and AS Watson delaying plans. The article highlights a disconnect between record index levels and the reluctance of companies to go public, as investors remain cautious about AI valuations.
Pharma Biotools Report: Steady Top Line as Frontier AI Labs Move In
The Q2 2026 Pharma Biotools Report provides an analysis of recent VC activity and includes a link to PitchBook's proprietary market map of leading VC-backed companies in the space. Published August 28, 2026. Also newly published: APAC VC Boom analyst note, IPOs Are Not Dead but Demoted, Construction & Engineering Report: Datacenters Take Center Stage, Foodtech Report, and Mobility Tech Report.
Receive all future signals for Anthropic & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.